evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4 questions · 4 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 75%Low 1 · 25%Moderate 0 · 0%High 0 · 0%

Vitamin K antagonists vs no VKA

Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

Vitamin K antagonist (VKA) showed no clear difference in symptomatic catheter‐related thrombosis (up to 3 months) compared with no VKA (low certainty).

1 finding from 1 review

Vitamin K antagonists vs no VKA

Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether vitamin K antagonist (VKA) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with no VKA (very low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist (VKA)

Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist (VKA)

Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with vitamin K antagonist (VKA) (very low certainty).

1 finding from 1 review